Prostate Cancer - Results from #680

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity. July 4, 2024

Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units July 3, 2024

Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer July 3, 2024

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. July 3, 2024

Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. July 3, 2024

Social integration and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. July 3, 2024

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. July 3, 2024

Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. July 3, 2024

A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer. July 3, 2024

Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study. July 3, 2024

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. July 3, 2024

U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer July 2, 2024

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease? July 2, 2024

Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. July 2, 2024

Reducing Racial Inequalities in Prostate Cancer Treatment: Healthcare Access Barriers. July 2, 2024

Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting. July 2, 2024

Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. July 2, 2024

RECOVERY OF SOCIAL CONTINENCE AND SEXUAL FUNCTION IN MEN WITH HIGH-RISK PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: RESULTS FROM A STATEWIDE COLLABORATIVE. July 1, 2024

Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024). July 1, 2024

Negative biopsy histology in men with PI-RADS score 5: is it useful PSMA PET/CT evaluation? July 1, 2024

Page 35 of 1437